Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Journal
Lancet (London, England)
Journal Volume
401
Journal Issue
10373
Pages
269
Date Issued
2023-01-28
Author(s)
Verstovsek, Srdan
Gerds, Aaron T
Vannucchi, Alessandro M
Al-Ali, Haifa Kathrin
Lavie, David
Kuykendall, Andrew T
Grosicki, Sebastian
Iurlo, Alessandra
Goh, Yeow Tee
Lazaroiu, Mihaela C
Egyed, Miklos
Fox, Maria Laura
McLornan, Donal
Perkins, Andrew
Yoon, Sung-Soo
Gupta, Vikas
Kiladjian, Jean-Jacques
Granacher, Nikki
Lee, Sung-Eun
Ocroteala, Luminita
Passamonti, Francesco
Harrison, Claire N
Klencke, Barbara J
Ro, Sunhee
Donahue, Rafe
Kawashima, Jun
Mesa, Ruben
Abstract
Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen, and anaemia benefits in myelofibrosis. We aimed to confirm the differentiated clinical benefits of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, symptomatic patients with anaemia and intermediate-risk or high-risk myelofibrosis.
SDGs
Type
journal article